← Markets

STAAR Surgical Company

STAA · NASDAQ

Market closed$26.44$-2.54 (-8.76%)After hours $26.55 · +0.42%

Key statistics

Previous close$28.98
Open$27.31
Day high$27.31
Day low$24.65
52-week high$35.87
52-week low$15.59
Market cap1.32B
Volume1.90M
Average volume805.72K
P/E ratio46.39
Forward P/E—
EPS0.57
Dividend yield0.00%

Market context

Why it moved

STAAR Surgical shares dropped sharply after its preliminary Q2 2026 net sales of $90 million, while more than doubling year-over-year, came in essentially in line with — rather than meaningfully above — analyst consensus expectations, triggering a "sell the news" reaction compounded by ongoing leadership uncertainty, a slight EMEA revenue decline due to Middle East turmoil, and a broader market selloff led by chipmakers.

MarketbeatMarketchameleonFacebookPaYahoo Finance

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026STAAR Surgical tumbled nearly 9% — on volume more than double its average — in a classic 'sell the news' reaction after its preliminary Q2 2026 net sales of over $90 million, while more than doubling year-over-year, landed essentially in-line with the Street consensus of ~$90.2 million rather than delivering a meaningful beat. Investor caution was compounded by unresolved leadership questions (the company operates under interim co-CEOs), the absence of formal financial guidance, and an EMEA revenue decline tied to Middle East conflict. Wedbush reiterated its Outperform rating with a $40 price target and Canaccord Genuity maintained its Buy/$32 target, though both firms flagged the need for permanent management and reinstated guidance before raising conviction ahead of the full Q2 report on August 12.

-8.7647

July 17, 2026STAAR Surgical closed up modestly during the regular session but is plunging over 11% in after-hours trading after releasing preliminary Q2 2026 net sales that barely cleared $90 million — roughly in line with the $90.2 million analyst consensus but representing a dramatic doubling from $44.3 million a year ago. Investors appear disappointed by the company's warning that geopolitical and macroeconomic headwinds weighed on sales in the Middle East and parts of EMEA and Asia-Pacific, with management cautioning that if conditions persist or worsen, growth could be further impaired. Wedbush reiterated its Outperform rating with a $40 price target ahead of the release.

1.6842

July 16, 2026STAAR Surgical gained over 4% as Wedbush Securities reiterated its Outperform rating with a $40 price target, highlighting the company's dominant market position in phakic IOLs and competitive moat in implantable collamer lenses. The analyst note clarified that China demand softness reflects macro affordability pressures rather than a structural shift toward laser alternatives, while U.S. adoption headwinds are attributed to surgeon-training pipeline constraints — not product failures. STAAR also stood out as the top Q1 performer among medical device peers, posting 120% revenue growth and beating estimates by 20.8%, though shares have lagged since reporting.

4.2429

July 10, 2026STAAR Surgical closed modestly lower in the regular session and is extending those losses in after-hours trading, slipping an additional 2.3%, contrasting with a broadly flat healthcare sector (XLV). The stock has given back some ground despite a strong bullish narrative built around its Q1 2026 earnings beat — revenues of $93.5 million surged 120% year-over-year, far exceeding consensus — and analyst upgrades from Wedbush (Outperform, $40 PT) and Piper Sandler. Institutional models flagged elevated volatility in STAA today, and the stock remains down roughly 9.7% since its May earnings report despite the strong fundamentals, suggesting investors are still awaiting clearer guidance on Q2 and full-year outlook.

-0.7508

July 9, 2026STAAR Surgical closed modestly lower amid a cautious macro backdrop, as renewed U.S.-Iran hostilities pushed oil prices higher and reignited inflation fears, weighing on broader equities. The healthcare sector has been a relative outperformer in recent weeks—with XLV gaining 6.6% in June—providing some support for medical device names, though company-specific catalysts for STAAR remain limited near-term ahead of its next earnings report. Investors continue to monitor the global refractive surgery market and adoption trends for the company's implantable collamer lenses as a key long-term growth driver.

-0.6394

July 8, 2026STAAR Surgical surged over 6% in a standout session for healthcare, which posted its most significant relative strength in over 15 years with 91% of S&P 500 healthcare stocks advancing. The move came against a challenging macro backdrop — President Trump declared the U.S.-Iran ceasefire MOU 'over,' sending oil prices up 5%+ and dragging broader markets lower — yet STAAR and the healthcare sector decoupled sharply from the risk-off tape, benefiting from continued rotation out of technology into defensive and medtech names that has persisted for two consecutive weeks.

6.0264

July 7, 2026STAAR Surgical closed down nearly 3% in a broadly challenging session for healthcare stocks, underperforming the XLV sector ETF which held near its 52-week high. The decline came amid a risk-off tone across U.S. markets—the S&P 500 dropped roughly 52 points—as chip stocks sold off sharply, Treasury yields climbed with the 30-year above 5%, and investors weighed hawkish signals from new Fed Chair Kevin Warsh. Healthcare sector earnings are projected to decline year-over-year this quarter, adding headwinds for medical device names like STAAR Surgical.

-2.8895

July 7, 2026STAAR Surgical closed down roughly 1.6%, underperforming the broader healthcare sector as analyst skepticism weighs on sentiment. A recent critical piece from StockStory flagged concerns over deteriorating fundamentals — including a 5.7% annualized revenue decline over the past two years, a 26.6 percentage-point drop in margins over five years, and negative free cash flow of -18.9% — arguing the stock's 37× forward P/E leaves little room for error. Meanwhile, healthcare broadly faced headwinds on the day, with major sector names declining, even as the wider market was lifted by a semiconductor rebound.

-1.6193

Seeking Alpha · July 17, 2026STAAR Surgical's Punishment For Opacity Is Just (NASDAQ:STAA)Benzinga · July 17, 2026Caution Lingers for STAAR Surgical Amid Middle East Geopolitical TensionsBusiness Wire · July 16, 2026STAAR Surgical Announces Preliminary Net Sales for Second Quarter 2026Stock Titan · July 16, 2026STAAR Surgical expects Q2 sales above $90M amid regional headwindsInvesting.com · May 20, 2026STAAR Surgical signals standalone strength as Alcon overhang fades after strong Q1Investor's Business Daily · May 14, 2026Why It's Time To Take Profits In This Top-Rated Medical StockBusiness Wire · April 8, 2026STAAR Surgical Announces Preliminary Net Sales for First Quarter 2026Reuters · October 22, 2025Staar Surgical's top investor calls shareholder meeting to remove directors
Benzinga · July 17, 2026Caution Lingers for STAAR Surgical Amid Middle East Geopolitical Tensions
Mt Newswire · July 17, 2026Staar Surgical China Turnaround Continues to Boost Confidence, Wedbush Says
Mt Newswire · July 16, 2026STAAR Surgical Reports Higher Q2 Preliminary Net Sales
Benzinga · July 16, 2026STAAR Surgical Reports Q2 Preliminary Net Sales To Be Over $90M
Benzinga · July 16, 2026Wedbush Reiterates Outperform on Staar Surgical, Maintains $40 Price Target
Mt Newswire · July 15, 2026Staar Surgical's China ICL Demand Driven by Macro Affordability Pressures, Wedbush Says
Benzinga · May 29, 2026Wedbush Reiterates Outperform on Staar Surgical, Maintains $40 Price Target
Benzinga · May 15, 2026Wells Fargo Maintains Equal-Weight on Staar Surgical, Raises Price Target to $25

Peers

S&P 500SPX · $7,457.78-1.01%Alcon Inc.ALC · $70.26-0.51%Johnson & JohnsonJNJ · $253.04+1.23%Bausch Health Companies Inc.BHC · $4.83-2.03%Carl Zeiss Meditec AGAFX.DE · €29.30-2.33%The Cooper Companies, Inc.COO · $71.71-1.90%Align Technology, Inc.ALGN · $176.76-0.92%Merit Medical Systems, Inc.MMSI · $73.99-2.06%ICU Medical, Inc.ICUI · $157.51-2.87%Haemonetics CorporationHAE · $77.86-0.82%Avanos Medical, Inc.AVNS · $24.97+0.04%Neogen CorporationNEOG · $10.27-0.58%